PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.12%
Revenue growth above 1.5x AVGO's 6.32%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
12.17%
Gross profit growth above 1.5x AVGO's 4.96%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
6.58%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
6.58%
Operating income growth above 1.5x AVGO's 1.00%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
10.66%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
-11.11%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
6.67%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
22.61%
Share count expansion well above AVGO's 0.15%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.61%
Diluted share count expanding well above AVGO's 0.70%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-12.14%
Negative OCF growth while AVGO is at 9.32%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-92.82%
Negative FCF growth while AVGO is at 9.56%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
57.80%
10Y revenue/share CAGR under 50% of AVGO's 416.86%. Michael Burry would suspect a lasting competitive disadvantage.
57.80%
5Y revenue/share CAGR under 50% of AVGO's 134.28%. Michael Burry would suspect a significant competitive gap or product weakness.
57.80%
3Y revenue/share CAGR similar to AVGO's 62.33%. Walter Schloss would assume both companies experience comparable short-term cycles.
172.15%
10Y OCF/share CAGR under 50% of AVGO's 580.47%. Michael Burry would worry about a persistent underperformance in cash creation.
172.15%
5Y OCF/share CAGR above 1.5x AVGO's 92.77%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
172.15%
3Y OCF/share CAGR above 1.5x AVGO's 39.51%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
97.53%
Below 50% of AVGO's 869.72%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
97.53%
Below 50% of AVGO's 414.43%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
97.53%
3Y net income/share CAGR above 1.5x AVGO's 16.00%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
202.33%
Below 50% of AVGO's 862.23%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
202.33%
5Y equity/share CAGR 1.25-1.5x AVGO's 165.61%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
202.33%
3Y equity/share CAGR similar to AVGO's 201.93%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.61%
Our AR growth while AVGO is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-3.53%
Inventory is declining while AVGO stands at 8.08%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
3.36%
Asset growth above 1.5x AVGO's 0.60%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-8.46%
We have a declining book value while AVGO shows 5.15%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-0.12%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
20.07%
R&D growth drastically higher vs. AVGO's 13.26%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
13.57%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.